13815-87-7

Upstream product

• 1967-31-3 2-chloroterephthalic acid 
• 100-20-9 terephthaloyl chloride 
• 10388-10-0 2-chloro-1,4-bis-(trichloromethyl)-benzene 

Downstream Products

• 120824-90-0 bis(1-methylethyl) 2-chloro-1,4-benzenedicarboxylate 
• 70-09-7 2-chloro-N¹,N⁴-bis(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)terephthalamide 

Relevant academic research and scientific papers

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Identification and Structure-Activity Relationships of Novel Compounds that Potentiate the Activities of Antibiotics in Escherichia coli

In Gram-negative bacteria, efflux pumps are able to prevent effective cellular concentrations from being achieved for a number of antibiotics. Small molecule adjuvants that act as efflux pump inhibitors (EPIs) have the potential to reinvigorate existing antibiotics that are currently ineffective due to efflux mechanisms. Through a combination of rigorous experimental screening and in silico virtual screening, we recently identified novel classes of EPIs that interact with the membrane fusion protein AcrA, a critical component of the AcrAB-TolC efflux pump in Escherichia coli. Herein, we present initial optimization efforts and structure-activity relationships around one of those previously described hits, NSC 60339 (1). From these efforts we identified two compounds, SLUPP-225 (17h) and SLUPP-417 (17o), which demonstrate favorable properties as potential EPIs in E. coli cells including the ability to penetrate the outer membrane, improved inhibition of efflux relative to 1, and potentiation of the activity of novobiocin and erythromycin.

PROCESS FOR PRODUCING PHTHALIC ACID COMPOUND INCLUDING CHLORINATED AROMATIC RING

Provided is a process for producing a phthalic acid compound whose aromatic ring has been chlorinated, the process reacting a phthalic acid compound and chlorine in a mixture of chlorosulfonic acid and thionyl chloride in the presence of an iodine compound.

Process and intermediates for the preparation of halogenated protease inhibitors

This invention relates to novel intermediate compounds which are useful for producing the halogenated protease inhibitors that are the subject matter of U.S. Pat. No. 4,469,885. In particular, the invention relates to novel methods and intermediates for making said protease inhibitors, the intermediate compounds being of the formula: STR1 wherein R1 is: (a) straight or branched chain lower alkyl having 1-6 carbon atoms; or (b) H; wherein R6 is: (a) straight or branched chain higher alkyl having 13-25 carbon atoms; or (b) straight or branched chain higher alkenyl having 13-25 carbon atoms; wherein R5 is: (a) straight or branched chain lower alkyl having 1-6 carbon atoms; or (b) benzyl; wherein R7 is: (a) straight or branched chain lower alkyl having 1-6 carbon atoms; or (b) H; wherein R2 is: (a) --Cl, --Br, or --I; or (b) --CF3.